PAVmed Q2 FY26 GAAP net loss narrows to $5.48 million; revenue rises to $33,000
Reuters2026/08/14 12:01- PAVmed posted GAAP net loss attributable to common stockholders of $5.48 million, or $(0.87) a share, for Q2 2026.
- Operating expenses climbed to $7.06 million; revenue rose to $33,000.
- Non-GAAP adjusted net loss narrowed to $1.67 million, or $(0.27) a share.
- Cash and cash equivalents increased to $3.8 million as of June 30, 2026.
- Veris accelerated OSU-The James onboarding; implantable monitor neared design freeze ahead of early 2027 FDA 510(k) submission.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why hasn’t the rise in US Treasury yields boosted the US dollar exchange rate?
Gurman predicts iPhone Duo: The first foldable may set industry standards, Apple (AAPL.US) foldable could trigger a decade-long upgrade cycle
Renowned financial journalist Mark Gurman stated that Apple’s first foldable iPhone has the potential to elevate the still-experimental foldable phone category to an industry standard. He noted that this device, called the iPhone Duo, is one of Apple’s most influential products, ranking just behind the iMac, iPod, iPad, and Apple Watch.
Element Fleet drops bid for FleetPartners, exits sale process
Anchoring to Nasdaq! Anthropic races toward a record-breaking IPO with fundraising scale targeting SpaceX
Sources indicate that Anthropic PBC has chosen Nasdaq as its listing venue, and the potential IPO is expected to set a historic record.
Crypto prices
More
